Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US
This study complements the FIGHT-202 clinical trial by assessing the use of pemigatinib among a diverse population of patients with CCA under real-world conditions. Findings support the clinical benefit of pemigatinib demonstrated in FIGHT-202.
Authors
- Kristin M. Zimmerman Savill (ORCID: https://orcid.org/0000-0003-3442-7320)
- Richard D. Kim (ORCID: https://orcid.org/0000-0002-8448-844X)
- Michael Rodriguez (ORCID: https://orcid.org/0000-0002-8105-3547)
- Bruce A. Feinberg (ORCID: https://orcid.org/0000-0001-9267-9994)
- Cherrishe Brown‐Bickerstaff
- Kim Saverno (ORCID: https://orcid.org/0000-0002-3421-3755)
- Angele Kotomale
- Mike Blecker
- Haobo Ren
Institutions
- Moffitt Cancer Center (US)
- Cardinal Health (United States) (US)
- Incyte (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1093/oncolo/oyae204
- Citations
- 8
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.58
Funders
- Incyte
- Cardinal Health